Intuniv is owned by Takeda Pharms Usa.
Intuniv contains Guanfacine Hydrochloride.
Intuniv has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Intuniv are:
Intuniv was authorised for market use on 02 September, 2009.
Intuniv is available in tablet, extended release;oral dosage forms.
Intuniv can be used as treatment of attention-deficit hyperactivity disorder.
The generics of Intuniv are possible to be released after 04 January, 2023.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6811794||TAKEDA PHARMS USA||Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles|| |
(7 months ago)
|TAKEDA PHARMS USA||Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles|| |
(a month ago)
Market Authorisation Date: 02 September, 2009
Treatment: Treatment of attention-deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic